Acquisition synergies Following the acquisition by MaxCyte, position SeQure DX as the premier integrated source for gene editing risk assessment within a broader cell and gene therapy platform. Target opportunities with MaxCyte's pharma and biotech clients seeking end‑to‑end CGT solutions that combine cell engineering with robust off‑target analytics.

Regulatory confidence Emphasize regulatory alignment and a comprehensive assay suite (ONE-seq, GUIDE-seq, DEUX-seq, Amplicon-seq, Guide Profiler, Guide Select, SAFER Detection) as a means to de-risk programs, accelerate IND/CMC timelines, and support safety dossiers for clinical-stage and late-stage gene therapies.

Integrated solutions Leverage the existing technology stack and MaxCyte partnership to cross-sell bundled services that combine cell engineering with advanced risk assessment. Highlight streamlined workflows, data relevance across discovery to clinical, and potential joint offerings for risk mitigation in early development.

Growth momentum Capitalize on MaxCyte’s revenue trajectory and leadership recognition to approach prospective clients with proven market momentum. Position the combined entity as a trusted, high‑growth partner for developers needing scalable, compliant analytics as programs scale.

Strategic collaborations Target preclinical and early clinical programs through strategic platform licensing and collaborations, similar to the Moonlight Bio partnership. Identify biotech startups and mid‑sized CGT developers seeking accelerated safety validation and regulatory confidence to advance their pipelines.